ArticleThe Journal of infectious diseases2016
Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis.Bulletin of the World Health Organization · 2022Pooled it
- Bundibugyo virus disease evidence map: a rapid research needs appraisal.EClinicalMedicine · 2026Article
- Development of an immunochromatographic lateral flow assay for the rapid detection of all known orthoebolavirus glycoproteins.Npj viruses · 2026Article
- Adaptable, quantitative CRISPR/Cas12a-based assay for cytomegalovirus DNA in infant saliva.Scientific reports · 2026Article
- Successful Inactivation of High-Consequence Pathogens in PrimeStore Molecular Transport Media.Viruses · 2025Article
- Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.Recent advances in anti-infective drug discovery · 2024Review
- 50 Years of Lassa Fever Research.Current topics in microbiology and immunology · 2023Article
- 50 Years of Lassa Fever Research.Current topics in microbiology and immunology · 2023Article
- Technologies for Frugal and Sensitive Point-of-Care Immunoassays.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022Review
- Species-specific quantification of circulating ebolavirus burden using VP40-derived peptide variants.PLoS pathogens · 2021Article
- Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.Science translational medicine · 2021Article
- Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus.PLoS neglected tropical diseases · 2020Article
- Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection.Microorganisms · 2020Article
- Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.Scientific reports · 2020Article
- Early detection of Ebola virus proteins in peripheral blood mononuclear cells from infected mice.Clinical proteomics · 2020Article
- Characterization and analytical validation of a new antigenic rapid diagnostic test for Ebola virus disease detection.PLoS neglected tropical diseases · 2020Article
- Development and validation of a pen side test for Rift Valley fever.PLoS neglected tropical diseases · 2019Article
- Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus.Diagnostic pathology · 2018Article
- Analysis of CD8Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Needle lost in the haystack: multiple reaction monitoring fails to detectF1000Research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundEbola virus disease (EVD) is a severe viral illness caused by Ebola virus (EBOV). The 2013-2016 EVD outbreak in West Africa is the largest recorded, with >11 000 deaths. Development of the ReEBOV Antigen Rapid Test (ReEBOV RDT) was expedited to provide a point-of-care test for suspected EVD cases.
methodsRecombinant EBOV viral protein 40 antigen was used to derive polyclonal antibodies for RDT and enzyme-linked immunosorbent assay development. ReEBOV RDT limits of detection (LOD), specificity, and interference were analytically validated on the basis of Food and Drug Administration (FDA) guidance.
resultsThe ReEBOV RDT specificity estimate was 95% for donor serum panels and 97% for donor whole-blood specimens. The RDT demonstrated sensitivity to 3 species of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus) associated with human disease, with no cross-reactivity by pathogens associated with non-EBOV febrile illness, including malaria parasites. Interference testing exhibited no reactivity by medications in common use. The LOD for antigen was 4.7 ng/test in serum and 9.4 ng/test in whole blood. Quantitative reverse transcription-polymerase chain reaction testing of nonhuman primate samples determined the range to be equivalent to 3.0 × 10
conclusionsThe analytical validation presented here contributed to the ReEBOV RDT being the first antigen-based assay to receive FDA and World Health Organization emergency use authorization for this EVD outbreak, in February 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.